ArticleJournal of veterinary emergency and critical care (San Antonio, Tex. : 2001)
Multicenter Retrospective Study of Xenotransfusion of Canine Plasma Products to Cats: 14 Cases (2022-2024).
Article in Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the indications, transfusion protocols, transfusion reactions, and outcomes of cats that received canine plasma products.
designRetrospective, descriptive study from 2022 to 2024.
settingMulticenter study from one university teaching hospital and two private referral hospitals. ANIMALS: Fourteen client-owned cats that were transfused with canine plasma products and had transfusion records available.
interventionsNone. MEASUREMENTS AND MAIN
resultsFourteen cats received 16 canine plasma transfusions. The reasons for canine plasma xenotransfusion were confirmed coagulopathy (7/14), suspected coagulopathy (1/14), oncotic support (5/14), and severe hypovolemia (1/14). Six cats were found to be coagulopathic based on pretransfusion activated partial thromboplastin time (aPTT) and prothrombin time (PT). Three of these cats achieved normalization of both PT and aPTT after plasma xenotransfusion; one cat achieved normalization of PT only, and one cat had normalization of aPTT and mild prolongation of PT posttransfusion (<1.5-fold elevation of the upper reference interval). The median volume of canine plasma products administered was 11.35 mL/kg (range: 5.25-31.9), and the median time in which the plasma xenotransfusion was completed was 3.9 h (range: 0.15-24). Only six cats received canine plasma products exclusively. Of these six cats, two (33.3%) were suspected to experience signs of acute transfusion reactions, categorized as acute respiratory distress. Five cats (35.7%) survived to discharge, six (42.9%) were euthanized, and three (21.4%) experienced cardiopulmonary arrest.
conclusionsCanine plasma xenotransfusions to cats can be considered a life-saving option in the absence of feline plasma products for the treatment of coagulopathies and colloidal support. However, the safety profile of canine plasma transfusions in cats remains to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.